New Endpoints Innovative clinical trial design to facilitate schizophrenia drug development… FDA and National Institute of Mental Health (NIMH)
{"Image DocumentName": "New EndpointsInnovative clinical trial design to facilitate schizophrenia drug development\u2026 FDA and National Institute of Mental Health (NIMH)", "Image ImageDescription": "MATRICS clinical trial guidelines designed to facilitate novel compound development to treat cognitive impairment from schizophrenia (MATRICS) clinical trial guidelines for cognitive-enhancing drugs in schizophrenia.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}